Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine carcinoma of the skin arising from Merkel cells, specialized mechanoreceptor cells in the basal epidermis. MCC has two distinct etiologies: approximately 80% of cases are caused by clonal integration of Merkel cell polyomavirus (MCPyV) with expression of viral T antigens, while the remaining 20% are virus-negative and driven by UV-induced mutations resulting in high tumor mutational burden. MCC is highly aggressive with significant metastatic potential, but also immunogenic. Immune checkpoint inhibitors (avelumab, pembrolizumab) have transformed treatment of advanced MCC, with response rates of 50-70% and durable responses in many patients.
Ask a research question about Merkel Cell Carcinoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Merkel Cell Carcinoma
creation_date: '2026-01-26T02:55:13Z'
description: >-
Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine carcinoma of the
skin arising from Merkel cells, specialized mechanoreceptor cells in the basal
epidermis. MCC has two distinct etiologies: approximately 80% of cases are caused
by clonal integration of Merkel cell polyomavirus (MCPyV) with expression of viral
T antigens, while the remaining 20% are virus-negative and driven by UV-induced
mutations resulting in high tumor mutational burden. MCC is highly aggressive with
significant metastatic potential, but also immunogenic. Immune checkpoint inhibitors
(avelumab, pembrolizumab) have transformed treatment of advanced MCC, with response
rates of 50-70% and durable responses in many patients.
categories:
- Skin Cancer
- Neuroendocrine Tumor
- Virus-Associated Cancer
parents:
- skin carcinoma
- neuroendocrine carcinoma
has_subtypes:
- name: MCPyV-Positive Merkel Cell Carcinoma
description: >-
Virus-driven MCC containing clonally integrated Merkel cell polyomavirus
with expression of viral T antigens (small T and truncated large T antigens).
Accounts for approximately 80% of MCC cases. Generally has lower tumor
mutational burden than virus-negative MCC.
- name: MCPyV-Negative Merkel Cell Carcinoma
description: >-
UV-induced MCC lacking viral integration. Characterized by high tumor
mutational burden with UV signature mutations, including frequent RB1
inactivation. Accounts for approximately 20% of MCC cases.
infectious_agent:
- name: Merkel Cell Polyomavirus
description: >-
MCPyV is a small DNA virus that clonally integrates into the host genome in
approximately 80% of MCC cases. The virus expresses small T antigen (which
promotes cell proliferation) and a truncated large T antigen (which retains
RB1 binding but loses replication capacity). Viral T antigens drive
tumorigenesis and are essential for tumor maintenance.
evidence:
- reference: PMID:41232971
reference_title: "[Merkel carcinoma]."
supports: SUPPORT
snippet: "Two subtypes have been identified: Merkel polyomavirus-related (MCPyV), present in 80% of cases in Europe, and UV-related."
explanation: "Supports the high prevalence of MCPyV-positive Merkel cell carcinoma."
infectious_agent_term:
preferred_term: Merkel cell polyomavirus
term:
id: NCBITaxon:493803
label: Merkel cell polyomavirus
pathophysiology:
- name: Viral T Antigen Oncogenesis
conforms_to: "viral_oncogenesis#Viral Oncoprotein Expression and Genome Integration"
description: >-
In MCPyV-positive MCC, clonally integrated virus expresses truncated large
T antigen (LT) that binds and inactivates RB tumor suppressor protein,
releasing E2F transcription factors and driving cell cycle progression.
Small T antigen (sT) promotes proliferation through multiple mechanisms
including 4E-BP1 hyperphosphorylation and cap-dependent translation.
evidence:
- reference: PMID:18202256
reference_title: "Clonal integration of a polyomavirus in human Merkel cell carcinoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In six of eight MCV-positive MCCs, viral DNA was integrated within the tumor genome in a clonal pattern, suggesting that MCV infection and integration preceded clonal expansion of the tumor cells."
explanation: "Establishes clonal integration of MCPyV preceding tumor expansion, the basis of viral T-antigen-driven oncogenesis."
- reference: PMID:18812503
reference_title: "T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "tumor-derived virus mutations do not affect retinoblastoma tumor suppressor protein (Rb) binding by LT but do eliminate viral DNA replication capacity."
explanation: "Shows the tumor-specific truncated large T antigen retains RB binding while losing replication capacity, driving proliferation."
cell_types:
- preferred_term: Merkel cell
term:
id: CL:0000242
label: Merkel cell
biological_processes:
- preferred_term: cell population proliferation
modifier: INCREASED
term:
id: GO:0008283
label: cell population proliferation
locations:
- preferred_term: skin of body
term:
id: UBERON:0002097
label: skin of body
downstream:
- target: RB1 Pathway Inactivation
description: Viral LT antigen sequesters and inactivates pRB protein
- name: RB1 Pathway Inactivation
conforms_to: "viral_oncogenesis#Host Tumor Suppressor Inactivation and Signaling Hijack"
description: >-
In virus-positive MCC, viral large T antigen binds and inactivates RB1 protein.
In virus-negative MCC, RB1 is frequently inactivated by somatic mutations.
In both cases, loss of RB1 function releases E2F transcription factors to
drive cell cycle progression and proliferation.
evidence:
- reference: PMID:26238782
reference_title: "The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Merkel cell polyomavirus (MCPyV) may contribute to tumorigenesis in a subset of tumors via inhibition of tumor suppressors such as retinoblastoma (RB1) by mutated viral T antigens"
explanation: "Documents RB1 inactivation by viral T antigens as a shared oncogenic route, complemented by somatic RB1 mutation in virus-negative MCC."
biological_processes:
- preferred_term: cell population proliferation
modifier: INCREASED
term:
id: GO:0008283
label: cell population proliferation
downstream:
- target: Uncontrolled Merkel Cell Proliferation
description: E2F activation drives expression of cell cycle genes
- name: UV-Induced Mutagenesis
description: >-
In virus-negative MCC (approximately 20%), high levels of UV-induced mutations
(C>T transitions at dipyrimidine sites) drive oncogenesis. These tumors have
among the highest tumor mutational burdens of any cancer and frequently
harbor mutations in TP53, RB1, and other tumor suppressors.
evidence:
- reference: PMID:26238782
reference_title: "The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "MCPyV-negative tumors also displayed high overall mutation burden (10.09 ± 2.32 mutations/Mb) and were characterized by a prominent UV-signature pattern with C > T transitions comprising 85% of mutations."
explanation: "Quantifies the high UV-signature mutational burden that drives virus-negative MCC."
cell_types:
- preferred_term: Merkel cell
term:
id: CL:0000242
label: Merkel cell
biological_processes:
- preferred_term: cell population proliferation
modifier: INCREASED
term:
id: GO:0008283
label: cell population proliferation
locations:
- preferred_term: skin of body
term:
id: UBERON:0002097
label: skin of body
- name: Uncontrolled Merkel Cell Proliferation
description: >-
Whether driven by viral T antigens or UV-induced mutations, MCC cells exhibit
uncontrolled proliferation. The neuroendocrine differentiation is retained,
with expression of characteristic markers including CK20, chromogranin,
and synaptophysin.
cell_types:
- preferred_term: Merkel cell
term:
id: CL:0000242
label: Merkel cell
biological_processes:
- preferred_term: cell population proliferation
modifier: INCREASED
term:
id: GO:0008283
label: cell population proliferation
histopathology:
- name: Cutaneous Neuroendocrine Carcinoma
finding_term:
preferred_term: Merkel Cell Carcinoma
term:
id: NCIT:C9231
label: Merkel Cell Carcinoma
frequency: VERY_FREQUENT
description: Merkel carcinoma is a highly aggressive cutaneous neuroendocrine carcinoma.
evidence:
- reference: PMID:41232971
reference_title: "[Merkel carcinoma]."
supports: SUPPORT
snippet: "Merkel's carcinoma is a rare but highly aggressive cutaneous neuroendocrine"
explanation: Abstract describes Merkel carcinoma as a highly aggressive cutaneous neuroendocrine tumor.
phenotypes:
- category: Dermatologic
name: Neuroendocrine Neoplasm
frequency: OBLIGATE
diagnostic: true
description: >-
Merkel cell carcinoma is a high-grade neuroendocrine carcinoma with
characteristic small round blue cell histology and neuroendocrine marker
expression (synaptophysin, chromogranin, CD56).
phenotype_term:
preferred_term: Neuroendocrine neoplasm
term:
id: HP:0100634
label: Neuroendocrine neoplasm
- category: Dermatologic
name: Cutaneous Nodule
frequency: VERY_FREQUENT
diagnostic: true
description: >-
Rapidly growing, firm, painless, dome-shaped nodule typically red or
violaceous in color. Often described by AEIOU criteria: Asymptomatic,
Expanding rapidly, Immunosuppression, Older age, UV-exposed site.
phenotype_term:
preferred_term: Neoplasm of the skin
term:
id: HP:0008069
label: Neoplasm of the skin
environmental:
- name: Ultraviolet Radiation
exposure_term:
preferred_term: exposure to ultraviolet radiation
term:
id: ECTO:0000006
label: exposure to ultraviolet radiation
description: >-
UV exposure is a major risk factor for MCC. Most tumors occur on sun-exposed
skin. UV signature mutations are characteristic of virus-negative MCC.
evidence:
- reference: PMID:33252781
reference_title: "Merkel cell carcinoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Merkel cell polyomavirus has been shown to induce gene mutations resulting in this skin cancer, with immunosuppression and ultraviolet radiation being other key risk factors in its pathogenesis"
explanation: Clinical review naming ultraviolet radiation as a key risk factor in MCC pathogenesis alongside MCPyV and immunosuppression.
- name: Immunosuppression
exposure_term:
preferred_term: immunosuppression
term:
id: ECTO:9001747
label: exposure to immunosuppressive agent
description: >-
Immunosuppression dramatically increases MCC risk (10-15 fold in organ
transplant recipients). This suggests immune surveillance normally
controls MCPyV-infected cells.
evidence:
- reference: PMID:18202256
reference_title: "Clonal integration of a polyomavirus in human Merkel cell carcinoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Merkel cell carcinoma (MCC) is a rare but aggressive human skin cancer that typically affects elderly and immunosuppressed individuals, a feature suggestive of an infectious origin."
explanation: "Notes the predisposition of immunosuppressed individuals to MCC, consistent with impaired immune control of MCPyV."
genetic:
- name: MCPyV T Antigens
association: Viral Oncogenes
notes: >-
In MCPyV-positive MCC, viral small T and truncated large T antigens are
the primary oncogenic drivers. Large T antigen binds RB1, while small T
antigen promotes proliferation through multiple mechanisms. Tumors are
addicted to viral oncoprotein expression.
evidence:
- reference: PMID:18812503
reference_title: "T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Nine MCC tumor-derived LT genomic sequences have been examined, and all were found to harbor mutations prematurely truncating the MCV LT helicase."
explanation: "Tumor-specific truncating LT mutations define the MCPyV T-antigen driver signature in MCC."
- name: RB1
gene_term:
preferred_term: RB1
term:
id: hgnc:9884
label: RB1
association: Somatic Mutations (in MCPyV-negative MCC)
notes: >-
RB1 mutations occur in the majority of MCPyV-negative MCC but are
virtually absent in virus-positive tumors, where viral LT antigen
functionally inactivates RB1 protein.
evidence:
- reference: PMID:26238782
reference_title: "The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In addition to previously identified mutations in TP53, RB1, and PIK3CA, we discovered activating mutations of oncogenes, including HRAS and loss-of-function mutations in PRUNE2 and NOTCH family genes in MCPyV-negative MCC."
explanation: "Confirms recurrent somatic RB1 (and TP53) mutations in virus-negative MCC."
- name: TP53
gene_term:
preferred_term: TP53
term:
id: hgnc:11998
label: TP53
association: Somatic Mutations (in MCPyV-negative MCC)
notes: >-
TP53 mutations with UV signature are common in virus-negative MCC.
Virus-positive tumors retain wild-type TP53, suggesting different
selective pressures.
evidence:
- reference: PMID:26238782
reference_title: "The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In addition to previously identified mutations in TP53, RB1, and PIK3CA, we discovered activating mutations of oncogenes, including HRAS and loss-of-function mutations in PRUNE2 and NOTCH family genes in MCPyV-negative MCC."
explanation: "Confirms recurrent somatic TP53 mutations in virus-negative MCC, alongside the UV mutational signature."
treatments:
- name: Avelumab
description: >-
Anti-PD-L1 antibody approved for metastatic MCC. First immune checkpoint
inhibitor approved for MCC based on durable responses in the JAVELIN Merkel
200 trial. Response rates of approximately 30-35% in previously treated
patients and higher in first-line setting.
treatment_term:
preferred_term: immunotherapy
term:
id: NCIT:C15262
label: Immunotherapy
therapeutic_agent:
- preferred_term: avelumab
term:
id: NCIT:C116870
label: Avelumab
evidence:
- reference: NCIT:C116870
reference_title: "Avelumab (NCIT)"
supports: SUPPORT
evidence_source: OTHER
snippet: "Avelumab | Accepted_Therapeutic_Use_For | - | - | locally advanced or metastatic urothelial carcinoma; metastatic Merkel cell carcinoma (MCC); advanced renal cell carcinoma (RCC)."
explanation: >-
NCI Thesaurus asserts accepted therapeutic use of avelumab for metastatic
Merkel cell carcinoma.
- name: Pembrolizumab
description: >-
Anti-PD-1 antibody approved for advanced MCC. Response rates of approximately
50-70% with durable responses. Both virus-positive and virus-negative MCC
respond to checkpoint inhibition.
treatment_term:
preferred_term: immunotherapy
term:
id: NCIT:C15262
label: Immunotherapy
therapeutic_agent:
- preferred_term: pembrolizumab
term:
id: NCIT:C106432
label: Pembrolizumab
evidence:
- reference: PMID:27093365
reference_title: "PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The response rate was 62% among patients with MCPyV-positive tumors (10 of 16 patients) and 44% among those with virus-negative tumors (4 of 9 patients)."
explanation: "First-line pembrolizumab produced durable responses in both virus-positive and virus-negative advanced MCC."
- name: Surgical Excision
description: >-
Wide local excision with adequate margins (1-2 cm) is the primary treatment
for localized MCC. Sentinel lymph node biopsy is recommended given high
rate of occult nodal metastases.
treatment_term:
preferred_term: Excision
term:
id: NCIT:C15232
label: Excision
- name: Radiation Therapy
description: >-
MCC is radiosensitive. Adjuvant radiation improves local control,
particularly for tumors with high-risk features. Radiation may be used
as primary treatment for unresectable tumors.
therapeutic_modality: RADIOTHERAPY
treatment_term:
preferred_term: Radiation Therapy
term:
id: NCIT:C15313
label: Radiation Therapy
- name: Chemotherapy
description: >-
MCC is chemosensitive (like other small cell carcinomas) with initial
response rates of 50-60% to platinum/etoposide regimens. However,
responses are typically short-lived and chemotherapy has been largely
supplanted by immunotherapy.
treatment_term:
preferred_term: Chemotherapy
term:
id: NCIT:C15632
label: Chemotherapy
disease_term:
preferred_term: Merkel cell carcinoma
term:
id: MONDO:0019210
label: cutaneous neuroendocrine carcinoma
notes: >-
MCC is a paradigm for both viral oncogenesis and immunotherapy responsiveness.
The dual etiology (viral versus UV-induced) highlights different mechanisms
leading to the same tumor type. The high immunogenicity of MCC, whether due
to viral antigens or high mutational burden, underlies the remarkable
responses to checkpoint inhibitors. Viral T antigens represent potential
targets for T-cell based therapies. The association with immunosuppression
underscores the importance of immune surveillance in controlling this tumor.
classifications:
icdo_morphology:
classification_value: Carcinoma
harrisons_chapter:
- classification_value: ONCOLOGY_HEMATOLOGY
nih_research_priority:
- classification_value: NIH_HT_42_rare_cancers_across_cancer_control_continuum
notes: Rare, aggressive cutaneous neuroendocrine carcinoma (Merkel cell polyomavirus-driven viral oncogenesis) — a flagship rare-cancer exemplar for NIH Highlighted Topic 42 (rare cancers across the cancer control continuum).
references:
- reference: DOI:10.1002/cam4.5890
title: Avelumab for the treatment of locally advanced or metastatic Merkel cell carcinoma—A multicenter real‐world experience in Israel
found_in:
- Merkel_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: Merkel cell carcinoma (MCC) is a rare and aggressive malignancy of the skin, affecting predominantly the fair‐skinned older population exposed to high levels of ultraviolet light.
supporting_text: Merkel cell carcinoma (MCC) is a rare and aggressive malignancy of the skin, affecting predominantly the fair‐skinned older population exposed to high levels of ultraviolet light.
evidence:
- reference: DOI:10.1002/cam4.5890
reference_title: Avelumab for the treatment of locally advanced or metastatic Merkel cell carcinoma—A multicenter real‐world experience in Israel
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Merkel cell carcinoma (MCC) is a rare and aggressive malignancy of the skin, affecting predominantly the fair‐skinned older population exposed to high levels of ultraviolet light.
explanation: Deep research cited this publication as relevant literature for Merkel Cell Carcinoma.
- reference: DOI:10.1002/ski2.55
title: Merkel Cell Carcinoma
found_in:
- Merkel_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: Merkel cell carcinoma (MCC) is a rare neuroendocrine carcinoma.
supporting_text: Merkel cell carcinoma (MCC) is a rare neuroendocrine carcinoma.
evidence:
- reference: DOI:10.1002/ski2.55
reference_title: Merkel Cell Carcinoma
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Merkel cell carcinoma (MCC) is a rare neuroendocrine carcinoma.
explanation: Deep research cited this publication as relevant literature for Merkel Cell Carcinoma.
- reference: DOI:10.1007/s40257-024-00858-z
title: 'Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates'
found_in:
- Merkel_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: 'Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates'
supporting_text: 'Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates'
- reference: DOI:10.1016/j.esmoop.2024.103461
title: 'First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study'
found_in:
- Merkel_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: 'First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study'
supporting_text: 'First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study'
- reference: DOI:10.1136/jitc-2024-009396
title: 'Merkel cell carcinoma refractory to anti-PD(L)1: utility of adding ipilimumab for salvage therapy'
found_in:
- Merkel_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: Merkel cell carcinoma (MCC) incidence has risen to approximately 3,000 cases annually in the USA.
supporting_text: Merkel cell carcinoma (MCC) incidence has risen to approximately 3,000 cases annually in the USA.
evidence:
- reference: DOI:10.1136/jitc-2024-009396
reference_title: 'Merkel cell carcinoma refractory to anti-PD(L)1: utility of adding ipilimumab for salvage therapy'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Merkel cell carcinoma (MCC) incidence has risen to approximately 3,000 cases annually in the USA.
explanation: Deep research cited this publication as relevant literature for Merkel Cell Carcinoma.
- reference: DOI:10.1158/1078-0432.ccr-23-0395
title: Biomarker Analyses Investigating Disease Biology and Associations with Outcomes in the JAVELIN Merkel 200 Trial of Avelumab in Metastatic Merkel Cell Carcinoma
found_in:
- Merkel_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: 'Avelumab (anti–PD-L1) became the first approved treatment for metastatic Merkel cell carcinoma (mMCC) based on results from the phase II JAVELIN Merkel 200 trial.'
supporting_text: 'Avelumab (anti–PD-L1) became the first approved treatment for metastatic Merkel cell carcinoma (mMCC) based on results from the phase II JAVELIN Merkel 200 trial.'
evidence:
- reference: DOI:10.1158/1078-0432.ccr-23-0395
reference_title: Biomarker Analyses Investigating Disease Biology and Associations with Outcomes in the JAVELIN Merkel 200 Trial of Avelumab in Metastatic Merkel Cell Carcinoma
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: 'Avelumab (anti–PD-L1) became the first approved treatment for metastatic Merkel cell carcinoma (mMCC) based on results from the phase II JAVELIN Merkel 200 trial.'
explanation: Deep research cited this publication as relevant literature for Merkel Cell Carcinoma.
- reference: DOI:10.1186/s12885-024-13129-1
title: 'Efficacy and safety of PD-1/PD-L1 inhibitors in patients with Merkel Cell Carcinoma: a systematic review and Meta-analysis'
found_in:
- Merkel_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: 'Efficacy and safety of PD-1/PD-L1 inhibitors in patients with Merkel Cell Carcinoma: a systematic review and Meta-analysis'
supporting_text: 'Efficacy and safety of PD-1/PD-L1 inhibitors in patients with Merkel Cell Carcinoma: a systematic review and Meta-analysis'
- reference: DOI:10.1245/s10434-024-15478-4
title: The Role of Neoadjuvant Immunotherapy in the Management of Merkel Cell Carcinoma with Clinically Detected Regional Lymph Node Metastasis
found_in:
- Merkel_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: Immunotherapy is emerging as a promising option for certain locally advanced and metastatic cutaneous malignancies.
supporting_text: Immunotherapy is emerging as a promising option for certain locally advanced and metastatic cutaneous malignancies.
evidence:
- reference: DOI:10.1245/s10434-024-15478-4
reference_title: The Role of Neoadjuvant Immunotherapy in the Management of Merkel Cell Carcinoma with Clinically Detected Regional Lymph Node Metastasis
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Immunotherapy is emerging as a promising option for certain locally advanced and metastatic cutaneous malignancies.
explanation: Deep research cited this publication as relevant literature for Merkel Cell Carcinoma.
- reference: DOI:10.1371/journal.ppat.1006668
title: Merkel cell polyomavirus recruits MYCL to the EP400 complex to promote oncogenesis
found_in:
- Merkel_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: Merkel cell polyomavirus recruits MYCL to the EP400 complex to promote oncogenesis
supporting_text: Merkel cell polyomavirus recruits MYCL to the EP400 complex to promote oncogenesis
- reference: DOI:10.3389/fimmu.2023.1172913
title: Insights into anti-tumor immunity via the polyomavirus shared across human Merkel cell carcinomas
found_in:
- Merkel_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: Understanding and augmenting cancer-specific immunity is impeded by the fact that most tumors are driven by patient-specific mutations that encode unique antigenic epitopes.
supporting_text: Understanding and augmenting cancer-specific immunity is impeded by the fact that most tumors are driven by patient-specific mutations that encode unique antigenic epitopes.
evidence:
- reference: DOI:10.3389/fimmu.2023.1172913
reference_title: Insights into anti-tumor immunity via the polyomavirus shared across human Merkel cell carcinomas
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Understanding and augmenting cancer-specific immunity is impeded by the fact that most tumors are driven by patient-specific mutations that encode unique antigenic epitopes.
explanation: Deep research cited this publication as relevant literature for Merkel Cell Carcinoma.
- reference: DOI:10.3389/fonc.2024.1413793
title: 'Merkel cell carcinoma: updates in tumor biology, emerging therapies, and preclinical models'
found_in:
- Merkel_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma thought to arise via either viral (Merkel cell polyomavirus) or ultraviolet-associated pathways.
supporting_text: Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma thought to arise via either viral (Merkel cell polyomavirus) or ultraviolet-associated pathways.
evidence:
- reference: DOI:10.3389/fonc.2024.1413793
reference_title: 'Merkel cell carcinoma: updates in tumor biology, emerging therapies, and preclinical models'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma thought to arise via either viral (Merkel cell polyomavirus) or ultraviolet-associated pathways.
explanation: Deep research cited this publication as relevant literature for Merkel Cell Carcinoma.
- reference: DOI:10.3390/cancers15030609
title: Evolving Applications of Circulating Tumor DNA in Merkel Cell Carcinoma
found_in:
- Merkel_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: Circulating tumor DNA (ctDNA) is a subset of circulating cell-free DNA released by lysed tumor cells that can be characterized by its shorter strand length and tumor genome-specific information.
supporting_text: Circulating tumor DNA (ctDNA) is a subset of circulating cell-free DNA released by lysed tumor cells that can be characterized by its shorter strand length and tumor genome-specific information.
evidence:
- reference: DOI:10.3390/cancers15030609
reference_title: Evolving Applications of Circulating Tumor DNA in Merkel Cell Carcinoma
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Circulating tumor DNA (ctDNA) is a subset of circulating cell-free DNA released by lysed tumor cells that can be characterized by its shorter strand length and tumor genome-specific information.
explanation: Deep research cited this publication as relevant literature for Merkel Cell Carcinoma.
- reference: DOI:10.3390/cancers15205084
title: 'An Updated Review of the Biomarkers of Response to Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: Merkel Cell Carcinoma and Immunotherapy'
found_in:
- Merkel_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: Merkel cell carcinoma (MCC) is primarily a disease of the elderly Caucasian, with most cases occurring in individuals over 50.
supporting_text: Merkel cell carcinoma (MCC) is primarily a disease of the elderly Caucasian, with most cases occurring in individuals over 50.
evidence:
- reference: DOI:10.3390/cancers15205084
reference_title: 'An Updated Review of the Biomarkers of Response to Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: Merkel Cell Carcinoma and Immunotherapy'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Merkel cell carcinoma (MCC) is primarily a disease of the elderly Caucasian, with most cases occurring in individuals over 50.
explanation: Deep research cited this publication as relevant literature for Merkel Cell Carcinoma.
- reference: DOI:10.3390/cancers16112158
title: Incidence and Relative Survival of Patients with Merkel Cell Carcinoma in North Rhine-Westphalia, Germany, 2008–2021
found_in:
- Merkel_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: To date, only a few population-representative studies have been carried out on the rare Merkel cell carcinoma (MCC).
supporting_text: To date, only a few population-representative studies have been carried out on the rare Merkel cell carcinoma (MCC).
evidence:
- reference: DOI:10.3390/cancers16112158
reference_title: Incidence and Relative Survival of Patients with Merkel Cell Carcinoma in North Rhine-Westphalia, Germany, 2008–2021
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: To date, only a few population-representative studies have been carried out on the rare Merkel cell carcinoma (MCC).
explanation: Deep research cited this publication as relevant literature for Merkel Cell Carcinoma.
- reference: DOI:10.5582/irdr.2024.01061
title: "Classification and epidemiologic analysis of 86 diseases in <i>China's Second List of Rare Diseases </i>"
found_in:
- Merkel_Cell_Carcinoma-deep-research-falcon.md
findings:
- statement: Classification and epidemiologic analysis of 86 diseases in <i>China's Second List of Rare Diseases </i>
supporting_text: Classification and epidemiologic analysis of 86 diseases in <i>China's Second List of Rare Diseases </i>
datasets:
- accession: ega:EGAS00001003784
title: Polyomavirus-positive Merkel cell carcinoma derived from a trichoblastoma suggests an epithelial origin of Merkel cell carcinoma
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Merkel Cell Carcinoma"); description-level mentions were not accepted. EGA study_type: Cancer Genomics. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001005028
title: 'Merkel cell polyomavirus-negative -Merkel cell carcinoma originating from in situ squamous cell carcinoma: a keratinocytic tumor with neuroendocrine differentiation'
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Merkel Cell Carcinoma"); description-level mentions were not accepted. EGA study_type: Cancer Genomics. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001008157
title: 'High-Resolution Spatial Transcriptomics Uncover Epidermal-Dermal Divergences in Merkel Cell Carcinoma: Spatial Context Reshapes the Gene Expression Landscape'
description: Merkel cell carcinoma (MCC) is an aggressive malignancy with neuroendocrine differentiation marked by high plasticity, often manifesting as rapid therapy resistance. Although the cell-of-origin is presumed to be epithelial, epidermal localization of MCC is rarely observed, largely because in situ MCC is typically an incidental finding. Nevertheless, a subset of MCC tumors exhibits epidermotropism, wherein tumor cells are present in the epidermis. The behavior of cancer cells is profoundly influenced by the tumor microenvironment and interactions with neighboring cells. Notably, the normal counterparts of the cancer’s cell-of-origin have been shown to attenuate tumor aggressiveness.
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Merkel Cell Carcinoma"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: massive:MSV000080262
title: Proteomic analysis of extracellular vesicles derived from Merkel cell carcinoma cell lines
description: Exosomes constitute an evolutionary conserved mechanism of intercellular signaling. Their importance are gaining increasing such as prognostic and diagnostic markers, and potential therapeutic tool. Merkel cell carcinoma (MCC) is an aggressive form of skin cancer with a poor prognosis. There are not available an effective systemic treatment for this type of cancer, and exosome-based therapy was proposed. We identified with high confident 164 exosome-derived proteins that were common for all four cell lines, which were annotated in ExoCarta and Vesiclepedia databases.
notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Merkel Cell Carcinoma"). Retrieved 2026-08-02.
- accession: massive:MSV000087251
title: Systematic evaluation and modulation of HLA class I downregulation in Merkel cell carcinoma
description: Lee PC, Klaeger S, Le PM, Korthauer K, Cheng J, Wong A, Tarren A, Lemvigh C, Sarkizova S, Li L, Frost TC, Nomburg J, Liu X, Pomerance L, Doherty L, Witten E, Zhang W, Apffel A, Wallace L, Neuberg D, Olsen L, Thakuria M, Clauser K, Starrett G, Doench J, Buhrlage SJ, Carr SA, DeCaprio JA, Wu CJ, Keskin DB. 2021 Viruses avoid immune surveillance through an array of mechanisms, including perturbation of HLA class I (HLA I) antigen presentation.
notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Merkel Cell Carcinoma"). Retrieved 2026-08-02.
Merkel cell carcinoma (MCC) is a rare, clinically aggressive neuroendocrine malignancy of the skin that often metastasizes early and has a substantial risk of recurrence after initial treatment (chang2024theroleof pages 1-2, akaike2024merkelcellcarcinoma pages 1-2).
Commonly used synonyms/labels in the accessed sources include: - “Merkel cell carcinoma” and abbreviation “MCC” (chang2024theroleof pages 1-2, akaike2024merkelcellcarcinoma pages 1-2) - “Cutaneous neuroendocrine carcinoma” (used in rare-disease classification context; mapping to MCC implied but not formally resolved to a code in retrieved excerpt) (li2024classificationandepidemiologic pages 2-3)
Most epidemiology and outcomes evidence in this report is derived from aggregated disease-level sources including cancer registries, clinical trials, and meta-analyses (moraes2024efficacyandsafety pages 5-8, stang2024incidenceandrelative pages 3-5, d’angelo2024firstlineavelumabtreatment pages 3-4).
A central organizing concept in MCC biology is the dual-etiology model:
1) Virus-driven MCC caused by clonal integration and continued expression of Merkel cell polyomavirus (MCPyV) T antigens, and
2) UV-associated MCC characterized by UV mutagenesis and typically higher tumor mutational burden (TMB) (becker2024merkelcellcarcinoma pages 1-2, fojnica2023anupdatedreview pages 2-4).
A recent immunology-focused review states: “80% of cases are driven by Merkel cell polyomavirus (MCPyV) oncoproteins that must be continually expressed for tumor survival” (jani2023insightsintoantitumor pages 1-2).
UV exposure and immunosuppression are repeatedly cited as major risk factors (chang2024theroleof pages 1-2, cheng2017merkelcellpolyomavirus pages 1-2). A mechanistic paper explicitly notes: “Risk factors for developing MCC include immunosuppression and UV-induced DNA damage from excessive exposure to sunlight” (cheng2017merkelcellpolyomavirus pages 1-2).
Immunosuppression and aging: Clinical context sources emphasize chronic immunosuppression as a risk factor, and MCC is typically a disease of older adults, with high metastatic propensity (chang2024theroleof pages 1-2, akaike2024merkelcellcarcinoma pages 1-2).
High-quality protective-factor evidence (e.g., quantified effect sizes for sun protection or immunosuppression mitigation) was not present in the retrieved primary texts. However, because UV exposure is a major risk factor, UV avoidance/protection is a biologically plausible primary prevention strategy (see Prevention section) (cheng2017merkelcellpolyomavirus pages 1-2).
The strongest established interaction is that immune competence modulates tumor surveillance in a disease where either (i) viral antigens (MCPyV) or (ii) UV-derived neoantigens provide immunogenic targets; both etiologies are associated with high immunogenicity but differ in antigen source (becker2024merkelcellcarcinoma pages 1-2, jani2023insightsintoantitumor pages 1-2).
MCC often presents as a painless, rapidly growing cutaneous nodule on sun-exposed skin: - “painless, flesh-colored, rapidly growing nodule in a sun-exposed area” (chang2024theroleof pages 1-2) - “rapidly growing, red-to-violet nodule on sun-exposed areas” (mistry2021merkelcellcarcinoma pages 1-2)
A recent expert commentary summarizes early aggressive behavior: ~45% have lymph node involvement and ~6% have distant metastases at diagnosis (akaike2024merkelcellcarcinoma pages 1-2). The same source states that “approximately 40% of patients experience disease recurrence… typically within 2 years of initial treatment” (akaike2024merkelcellcarcinoma pages 1-2).
In an NCDB-based analysis used for neoadjuvant immunotherapy context, 5-year OS is reported to decline with increasing stage burden: ~40.3% (stage IIIA clinically occult nodes) to ~26.8% (stage IIIB clinically detected nodes) to ~13.5% (stage IV distant metastases) (chang2024theroleof pages 1-2).
Because MCC is a malignancy, many key “phenotypes” are oncology course features rather than congenital traits. Suggested HPO mappings: - Cutaneous nodule / skin tumor: Skin nodule (HP:0200149), Cutaneous neoplasm (candidate; verify exact HPO label), Rapidly progressive (HP:0003678) (clinical rapid growth) (chang2024theroleof pages 1-2, mistry2021merkelcellcarcinoma pages 1-2) - Pain phenotype: Absent pain / painless lesion (map to “Pain” HP:0012531 as “not present” in structured phenotyping) (chang2024theroleof pages 1-2) - Regional metastasis: Lymphadenopathy (HP:0002716) as a proxy for nodal involvement; “lymph node metastasis” is not a standard HPO term but can be captured via oncology extensions (akaike2024merkelcellcarcinoma pages 1-2) - Distant metastasis: Metastatic neoplasm (candidate term; verify) (akaike2024merkelcellcarcinoma pages 1-2) - Recurrence: Recurrent infections is inappropriate; instead represent as disease-course annotation (not well captured by core HPO). Use clinical data model fields for recurrence timing (akaike2024merkelcellcarcinoma pages 1-2).
Virus-positive MCC is typically characterized by MCPyV integration and lower somatic mutation burden, whereas MCPyV-negative tumors are often UV-driven with higher TMB (fojnica2023anupdatedreview pages 2-4, jani2023insightsintoantitumor pages 1-2).
A 2023 biomarker review provides an illustrative contrast where an MCPyV+ case showed TMB 7 mut/Mb vs an MCPyV− case 34 mut/Mb, with MCPyV status assessed by CM2B4 IHC (fojnica2023anupdatedreview pages 2-4).
A mechanistic study in MCPyV-positive MCC showed viral small T antigen (ST) recruits MYCL to the EP400 chromatin remodeling/histone acetyltransferase complex, with MYCL and EP400 required for MCC cell viability (cheng2017merkelcellpolyomavirus pages 1-2). This supports a viral-oncoprotein → transcriptional/epigenetic program → tumor maintenance causal chain.
MCC is a model tumor for anti-viral tumor immunity because antigens are shared across MCPyV-driven tumors. A review summarizes that shared MCPyV oncoproteins enable measurement of MCC-directed immunity, and notes immune evasion mechanisms including “transcriptional downregulation of MHC expression… and upregulation of inhibitory molecules including PD-L1” (jani2023insightsintoantitumor pages 1-2).
Exploratory biomarker analysis from the JAVELIN Merkel 200 avelumab trial describes subtype-associated immune context: MCPyV+ tumors with increased M2 macrophages and PD-L1 correlation; and in MCPyV− tumors, higher CD8+ T-cell density appeared associated with response (d’angelo2024biomarkeranalysesinvestigating pages 2-3).
UV-associated DNA damage is a repeatedly cited etiologic component (cheng2017merkelcellpolyomavirus pages 1-2, fojnica2023anupdatedreview pages 2-4).
MCPyV is the key infectious agent in a large fraction of MCC cases, and viral oncoproteins must be persistently expressed for tumor survival in virus-driven MCC (jani2023insightsintoantitumor pages 1-2).
MCPyV infection → clonal integration and expression of T antigens → perturbation of cell-cycle control (e.g., RB pathway via LT) and activation of epigenetic/transcriptional programs (e.g., ST–MYCL–EP400 complex) → immune evasion (MHC downregulation, PD-L1 upregulation) → tumor persistence and progression (jani2023insightsintoantitumor pages 1-2, cheng2017merkelcellpolyomavirus pages 1-2).
Chronic UV exposure → UV-induced DNA damage → high mutational burden / neoantigen landscape → selection for immune evasion phenotypes and aggressive neuroendocrine carcinoma phenotype → early metastasis/recurrence (cheng2017merkelcellpolyomavirus pages 1-2, fojnica2023anupdatedreview pages 2-4).
Primary tumor arises in skin (UBERON:0002097) (mistry2021merkelcellcarcinoma pages 1-2).
Neuroendocrine carcinoma phenotype; cell-of-origin remains debated, with evidence for lineage reprogramming models (ATOH1) in preclinical systems (pedersen2024merkelcellcarcinoma pages 14-15).
Predominantly affects older adults; aggressive growth is typical (akaike2024merkelcellcarcinoma pages 1-2, chang2024theroleof pages 1-2).
A population-based German registry analysis (North Rhine–Westphalia; 18 million population coverage) reported: - Age-standardized incidence 5.2 per million person-years (men) and 3.8 per million person-years (women) (2008–2021) (stang2024incidenceandrelative pages 3-5). - 5-year relative survival 58.8% in men and 70.7% in women, and “the first two years are particularly critical” (stang2024incidenceandrelative pages 3-5).
A 2024 commentary notes MCC incidence has risen to approximately 3,000 cases annually in the USA (akaike2024merkelcellcarcinoma pages 1-2).
No Mendelian inheritance pattern is established for typical MCC; most molecular discussion in retrieved sources concerns somatic and viral carcinogenesis rather than germline inheritance.
A 2023 review describes classic morphology and a practical diagnostic IHC panel: - Morphology: “small, round, and blue undifferentiated cells with high mitotic rate…” (fojnica2023anupdatedreview pages 2-4). - Typical IHC: CK20 positive and neuroendocrine markers synaptophysin and chromogranin-A; usually negative for melanoma markers (S-100, Melan-A, HMB-45), lymphoid markers (LCA), and TTF-1 (helpful vs metastatic small-cell lung carcinoma) (fojnica2023anupdatedreview pages 2-4).
Staging evaluation commonly includes nodal assessment (including SLNB when feasible), and cross-sectional imaging (CT/MRI) and/or PET as clinically indicated (mistry2021merkelcellcarcinoma pages 1-2, chang2024theroleof pages 1-2).
AMERK (MCPyV oncoprotein antibodies): A ctDNA-focused review states: “In these virus-positive cases, MCPyV oncoprotein antibody (AMERK) titers can be used to monitor disease progression, recurrence risk, and response to therapy” and recommends establishing baseline titers within ~3 months of surgery because titers decline after clinically evident disease is eliminated (prakash2023evolvingapplicationsof pages 2-4).
ctDNA (tumor-informed) for MRD/surveillance: The same review summarizes prospective evidence that ctDNA can precede clinically evident recurrence and provides near-term recurrence-risk estimates. In one cited prospective dataset (125 patients; 328 blood samples), recurrence risk within 60 days of a positive ctDNA test was estimated at 57%, while risk after a negative test was 0% within 60 days and 3% from 60–90 days (prakash2023evolvingapplicationsof pages 4-5).
MCC must be distinguished from metastatic small-cell lung carcinoma; CK20+/TTF-1− pattern supports MCC in appropriate clinical context (fojnica2023anupdatedreview pages 2-4).
Key quantitative survival outcomes from recent evidence are summarized in the table artifact below.
| Domain | Finding (with numbers) | Population/setting | Study design | Year | DOI/URL | Evidence type | Citation ID |
|---|---|---|---|---|---|---|---|
| Epidemiology / incidence | Age-standardized incidence: 5.2 per million person-years in men and 3.8 per million person-years in women | North Rhine-Westphalia, Germany; 2,164 newly diagnosed MCC cases (2008–2021) | Population-based cancer registry analysis | 2024 | https://doi.org/10.3390/cancers16112158 | Human registry | (stang2024incidenceandrelative pages 3-5) |
| Survival / prognosis | 5-year relative survival: 58.8% men vs 70.7% women; first 2 years after diagnosis were most critical | North Rhine-Westphalia, Germany; MCC registry cohort | Population-based cancer registry analysis | 2024 | https://doi.org/10.3390/cancers16112158 | Human registry | (stang2024incidenceandrelative pages 3-5) |
| Checkpoint inhibitor outcomes (avelumab, first-line) | 4-year OS rate 38%; median OS 20.3 months; 62.1% had died by data cutoff; no treatment-related deaths reported | Metastatic MCC, JAVELIN Merkel 200 part B, first-line avelumab | Phase II trial, long-term follow-up | 2024 | https://doi.org/10.1016/j.esmoop.2024.103461 | Human clinical trial | (d’angelo2024firstlineavelumabtreatment pages 3-4, d’angelo2024firstlineavelumabtreatment pages 4-6) |
| Checkpoint inhibitor outcomes (meta-analysis) | Pooled ORR 53.79% (95% CI 47.80–59.68); DCR 61.65% (54.85–68.03) | 563 patients for ORR; 552 for DCR across PD-1/PD-L1 studies in MCC | Systematic review and meta-analysis | 2024 | https://doi.org/10.1186/s12885-024-13129-1 | Human meta-analysis | (moraes2024efficacyandsafety pages 5-8) |
| Checkpoint inhibitor outcomes (meta-analysis) | Pooled OS 24 months 65.05% (44.04–81.49); OS 36 months 59.58% (39.62–76.81) | PD-1/PD-L1 blockade studies in MCC | Systematic review and meta-analysis | 2024 | https://doi.org/10.1186/s12885-024-13129-1 | Human meta-analysis | (moraes2024efficacyandsafety pages 5-8) |
| Checkpoint inhibitor outcomes (meta-analysis) | Pooled PFS 6 months 51.78% (37.83–65.45); 12 months 46.12% (29.44–63.72); 36 months 28.73% (16.57–45.02) | PD-1/PD-L1 blockade studies in MCC | Systematic review and meta-analysis | 2024 | https://doi.org/10.1186/s12885-024-13129-1 | Human meta-analysis | (moraes2024efficacyandsafety pages 5-8) |
| Checkpoint inhibitor safety (meta-analysis) | Any-grade TRAEs 61.72%; grade ≥3 TRAEs 17.60%; immune-related AEs 22.76%; discontinuation due to TRAEs 12.74%; treatment-related death 3.45% | PD-1/PD-L1 blockade studies in MCC | Systematic review and meta-analysis | 2024 | https://doi.org/10.1186/s12885-024-13129-1 | Human meta-analysis | (moraes2024efficacyandsafety pages 5-8) |
| Real-world avelumab | Real-world response rate 59%; disease-control rate 70%; 37% complete response; any-grade toxicity 34%; grade 3–4 toxicity 14%; discontinuation due to toxicity 6% | Israel multicenter cohort; 62 MCC patients, including 22% immunosuppressed | Retrospective multicenter real-world study | 2023 | https://doi.org/10.1002/cam4.5890 | Human real-world cohort | (averbuch2023avelumabforthe pages 4-5) |
| Neoadjuvant immunotherapy | 19.7% received NIO; primary tumor ypT0 45.2%; nodal ypN0 17.9%; combined ypT0 ypN0 16/223; matched 5-year OS 57% vs 44% (NIO vs no NIO) | NCDB MCC patients with clinically detected regional lymph node metastasis; 1,809 selected, 356 received NIO | National database retrospective comparative study | 2024 | https://doi.org/10.1245/s10434-024-15478-4 | Human registry/observational comparative study | (chang2024theroleof pages 1-2) |
| PD(L)1-refractory salvage therapy | Aggregate retrospective response rate 32% (13/41) with 4 CR and 9 PR; prospective study 31% (8/26) with 4 CR and 4 PR | Advanced MCC refractory to anti-PD(L)1; ipilimumab added, often with nivolumab | Review/commentary synthesizing prospective + retrospective salvage data | 2024 | https://doi.org/10.1136/jitc-2024-009396 | Human evidence synthesis | (akaike2024merkelcellcarcinoma pages 1-2) |
| PD(L)1-refractory salvage toxicity | Grade ≥III irAEs 29% in retrospective cohort (N=41) and 36% in prospective cohort (N=50); ~70% did not benefit | PD(L)1-refractory advanced MCC treated with CTLA-4 add-on approaches | Review/commentary synthesizing salvage studies | 2024 | https://doi.org/10.1136/jitc-2024-009396 | Human evidence synthesis | (akaike2024merkelcellcarcinoma pages 1-2) |
Table: This table compiles key quantitative results for Merkel cell carcinoma across epidemiology, prognosis, immunotherapy efficacy, safety, and real-world implementation. It is useful as a compact evidence summary for knowledge-base population and citation tracking.
Additionally, the 2024 JAVELIN Merkel 200 part B report shows overall survival curves (first-line avelumab) and OS stratified by PD-L1 status; these figures support the long-term survival claims and are included as visual evidence (d’angelo2024firstlineavelumabtreatment media 30169c3d, d’angelo2024firstlineavelumabtreatment media a5f140c8).
Local control commonly relies on surgery (wide local excision) and radiotherapy; systemic therapy is driven by stage and recurrence/metastasis risk (chang2024theroleof pages 1-2, fojnica2023anupdatedreview pages 2-4).
Recent evidence strongly supports PD-1/PD-L1 blockade as a mainstay of advanced MCC management: - First-line avelumab (JAVELIN Merkel 200 part B, 4-year follow-up): “4-year OS rate of 38%” and median OS 20.3 months were reported (ESMO Open; May 2024; https://doi.org/10.1016/j.esmoop.2024.103461) (d’angelo2024firstlineavelumabtreatment pages 3-4, d’angelo2024firstlineavelumabtreatment pages 4-6). OS curves are shown in the retrieved figure (d’angelo2024firstlineavelumabtreatment media 30169c3d). - Meta-analysis (2024, BMC Cancer) of PD-1/PD-L1 inhibitors in MCC reported pooled ORR 53.79% and grade ≥3 TRAEs 17.60% (https://doi.org/10.1186/s12885-024-13129-1) (moraes2024efficacyandsafety pages 5-8). - Real-world avelumab (Israel multicenter): real-world response rate 59%, disease-control rate 70%, complete response 37%, and grade 3–4 toxicity 14% (https://doi.org/10.1002/cam4.5890; Apr 2023) (averbuch2023avelumabforthe pages 4-5).
Retifanlimab regulatory note: A 2023 review states retifanlimab-dlwr (anti-PD-1) is FDA-approved (2023) among ICI options for MCC (fojnica2023anupdatedreview pages 2-4).
In an NCDB analysis of MCC with clinically detected regional lymph node metastasis, neoadjuvant immunotherapy use was ~19.7%, with ypT0 in 45.2% and improved overall survival in matched analysis (5-year OS 57% vs 44%) (https://doi.org/10.1245/s10434-024-15478-4; published online June 2024) (chang2024theroleof pages 1-2).
A 2024 commentary synthesizing prospective and retrospective data reports that adding ipilimumab (CTLA-4 blockade, often with nivolumab) after PD-(L)1 failure yields ~31–32% response rates, with grade ≥III irAEs in ~29–36%, and that ~70% will not benefit—supporting a major unmet need (https://doi.org/10.1136/jitc-2024-009396; July 2024) (akaike2024merkelcellcarcinoma pages 1-2).
Because UV-induced DNA damage is a documented risk factor for MCC, UV exposure reduction (sun-protective behaviors) is mechanistically justified, though MCC-specific intervention effect sizes were not available in the retrieved sources (cheng2017merkelcellpolyomavirus pages 1-2).
Secondary prevention is an active translational area: - MCPyV oncoprotein antibody (AMERK) titers for virus-positive MCC surveillance (prakash2023evolvingapplicationsof pages 2-4). - Tumor-informed ctDNA for minimal residual disease and early relapse detection; one synthesized prospective estimate suggests a 57% risk of clinically relevant recurrence within 60 days of a positive ctDNA test vs near-zero short-term risk after a negative test (prakash2023evolvingapplicationsof pages 4-5).
No naturally occurring, well-characterized MCC analog across non-human species was retrieved in the accessed texts. Veterinary/cross-species MCC-like neuroendocrine tumors may exist but would require targeted veterinary oncology searches.
A 2024 review of MCC biology and models highlights: - Strong reliance on transplantable models (cell line xenografts; emerging patient-derived xenografts) for drug testing (pedersen2024merkelcellcarcinoma pages 14-15). - Difficulty generating faithful GEMMs for MCC due to uncertain cell-of-origin; early MCPyV T antigen mouse models often produced epidermal hyperplasia/papillomas rather than neuroendocrine MCC (pedersen2024merkelcellcarcinoma pages 14-15). - ATOH1-driven lineage reprogramming plus sTAg in embryos can generate “small blue cell tumors resembling” MCC and expressing markers including K20 in the clumped/dot-like pattern typical of MCC (pedersen2024merkelcellcarcinoma pages 14-15). - No syngeneic immunocompetent MCC mouse model is currently available per this review, limiting immunotherapy preclinical modeling (pedersen2024merkelcellcarcinoma pages 14-15).
Recent literature converges on MCC as an immunogenic cancer with dual etiologies (viral antigens vs UV neoantigens) and a treatment paradigm dominated by immune checkpoint blockade, yet with a substantial fraction of patients (~50%) lacking durable benefit and therefore a persistent need for biomarkers and effective salvage regimens (jani2023insightsintoantitumor pages 1-2, akaike2024merkelcellcarcinoma pages 1-2, d’angelo2024biomarkeranalysesinvestigating pages 2-3). The most practice-changing real-world implementations in 2023–2024 are the expansion of PD-1/PD-L1 inhibitors as standard systemic therapy and the rapid maturation of blood-based surveillance (AMERK in virus-positive disease; ctDNA MRD surveillance particularly valuable for virus-negative disease) (prakash2023evolvingapplicationsof pages 2-4, prakash2023evolvingapplicationsof pages 4-5, d’angelo2024firstlineavelumabtreatment pages 3-4).
References
(chang2024theroleof pages 1-2): Jenny H. Chang, Daphne Remulla, Chase Wehrle, Kimberly P. Woo, Fadi S. Dahdaleh, Daniel Joyce, and Samer A. Naffouje. The role of neoadjuvant immunotherapy in the management of merkel cell carcinoma with clinically detected regional lymph node metastasis. Annals of Surgical Oncology, 31:6079-6087, Jun 2024. URL: https://doi.org/10.1245/s10434-024-15478-4, doi:10.1245/s10434-024-15478-4. This article has 11 citations and is from a domain leading peer-reviewed journal.
(akaike2024merkelcellcarcinoma pages 1-2): Tomoko Akaike, Austin J Jabbour, Peter H Goff, Song Y Park, Shailender Bhatia, and Paul Nghiem. Merkel cell carcinoma refractory to anti-pd(l)1: utility of adding ipilimumab for salvage therapy. Journal for ImmunoTherapy of Cancer, 12:e009396, Jul 2024. URL: https://doi.org/10.1136/jitc-2024-009396, doi:10.1136/jitc-2024-009396. This article has 4 citations and is from a domain leading peer-reviewed journal.
(NCT03747484 chunk 2): Joshua Veatch. Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer. Fred Hutchinson Cancer Center. 2019. ClinicalTrials.gov Identifier: NCT03747484
(NCT03599713 chunk 3): A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201). Incyte Corporation. 2019. ClinicalTrials.gov Identifier: NCT03599713
(li2024classificationandepidemiologic pages 2-3): Junfeng Li, Meilin Liu, Han Li, Xin Zhang, Xufei Xiang, Yiping Wang, Shuyi Wang, Jinxiang Han, and Yanqin Lu. Classification and epidemiologic analysis of 86 diseases in china's second list of rare diseases. Intractable & rare diseases research, 13 4:213-226, Nov 2024. URL: https://doi.org/10.5582/irdr.2024.01061, doi:10.5582/irdr.2024.01061. This article has 6 citations.
(li2024classificationandepidemiologic pages 1-2): Junfeng Li, Meilin Liu, Han Li, Xin Zhang, Xufei Xiang, Yiping Wang, Shuyi Wang, Jinxiang Han, and Yanqin Lu. Classification and epidemiologic analysis of 86 diseases in china's second list of rare diseases. Intractable & rare diseases research, 13 4:213-226, Nov 2024. URL: https://doi.org/10.5582/irdr.2024.01061, doi:10.5582/irdr.2024.01061. This article has 6 citations.
(moraes2024efficacyandsafety pages 5-8): Francisco Cezar Aquino de Moraes, Michele Kreuz, Isabella Christina Amaral de Lara, Artur de Oliveira Macena Lôbo, and Rommel Mario Rodríguez Burbano. Efficacy and safety of pd-1/pd-l1 inhibitors in patients with merkel cell carcinoma: a systematic review and meta-analysis. BMC Cancer, Nov 2024. URL: https://doi.org/10.1186/s12885-024-13129-1, doi:10.1186/s12885-024-13129-1. This article has 15 citations and is from a peer-reviewed journal.
(stang2024incidenceandrelative pages 3-5): Andreas Stang, Lennart Möller, Ina Wellmann, Kevin Claaßen, Hiltraud Kajüter, Selma Ugurel, and Jürgen C. Becker. Incidence and relative survival of patients with merkel cell carcinoma in north rhine-westphalia, germany, 2008–2021. Cancers, 16:2158, Jun 2024. URL: https://doi.org/10.3390/cancers16112158, doi:10.3390/cancers16112158. This article has 4 citations.
(d’angelo2024firstlineavelumabtreatment pages 3-4): S.P. D’Angelo, C. Lebbé, L. Mortier, A.S. Brohl, N. Fazio, J.-J. Grob, N. Prinzi, G.J. Hanna, J.C. Hassel, F. Kiecker, A. von Heydebreck, G. Güzel, and P. Nghiem. First-line avelumab treatment in patients with metastatic merkel cell carcinoma: 4-year follow-up from part b of the javelin merkel 200 study. ESMO Open, 9:103461, May 2024. URL: https://doi.org/10.1016/j.esmoop.2024.103461, doi:10.1016/j.esmoop.2024.103461. This article has 29 citations and is from a domain leading peer-reviewed journal.
(becker2024merkelcellcarcinoma pages 1-2): Jürgen C. Becker, Andreas Stang, David Schrama, and Selma Ugurel. Merkel cell carcinoma: integrating epidemiology, immunology, and therapeutic updates. American Journal of Clinical Dermatology, 25:541-557, Apr 2024. URL: https://doi.org/10.1007/s40257-024-00858-z, doi:10.1007/s40257-024-00858-z. This article has 38 citations and is from a peer-reviewed journal.
(fojnica2023anupdatedreview pages 2-4): Adnan Fojnica, Kenana Ljuca, Saghir Akhtar, Zoran Gatalica, and Semir Vranic. An updated review of the biomarkers of response to immune checkpoint inhibitors in merkel cell carcinoma: merkel cell carcinoma and immunotherapy. Cancers, 15:5084, Oct 2023. URL: https://doi.org/10.3390/cancers15205084, doi:10.3390/cancers15205084. This article has 26 citations.
(jani2023insightsintoantitumor pages 1-2): Saumya Jani, Candice D. Church, and Paul Nghiem. Insights into anti-tumor immunity via the polyomavirus shared across human merkel cell carcinomas. Frontiers in Immunology, May 2023. URL: https://doi.org/10.3389/fimmu.2023.1172913, doi:10.3389/fimmu.2023.1172913. This article has 9 citations and is from a peer-reviewed journal.
(cheng2017merkelcellpolyomavirus pages 1-2): Jingwei Cheng, Donglim Esther Park, Christian Berrios, Elizabeth A. White, Reety Arora, Rosa Yoon, Timothy Branigan, Tengfei Xiao, Thomas Westerling, Alexander Federation, Rhamy Zeid, Benjamin Strober, Selene K. Swanson, Laurence Florens, James E. Bradner, Myles Brown, Peter M. Howley, Megha Padi, Michael P. Washburn, and James A. DeCaprio. Merkel cell polyomavirus recruits mycl to the ep400 complex to promote oncogenesis. PLOS Pathogens, 13:e1006668, Oct 2017. URL: https://doi.org/10.1371/journal.ppat.1006668, doi:10.1371/journal.ppat.1006668. This article has 157 citations and is from a highest quality peer-reviewed journal.
(mistry2021merkelcellcarcinoma pages 1-2): K. Mistry, N. J. Levell, P. Craig, N. M. Steven, and Z. C. Venables. Merkel cell carcinoma. Skin Health and Disease, Jun 2021. URL: https://doi.org/10.1002/ski2.55, doi:10.1002/ski2.55. This article has 22 citations and is from a peer-reviewed journal.
(d’angelo2024biomarkeranalysesinvestigating pages 2-3): Sandra P. D’Angelo, Céleste Lebbé, Paul Nghiem, Andrew S. Brohl, Thomas Mrowiec, Trent Leslie, Sara Georges, Gülseren Güzel, and Parantu Shah. Biomarker analyses investigating disease biology and associations with outcomes in the javelin merkel 200 trial of avelumab in metastatic merkel cell carcinoma. Clinical Cancer Research, 30:4352-4362, Jul 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-0395, doi:10.1158/1078-0432.ccr-23-0395. This article has 9 citations and is from a highest quality peer-reviewed journal.
(pedersen2024merkelcellcarcinoma pages 13-14): Elisabeth A. Pedersen, Monique E. Verhaegen, Mallory K. Joseph, Kelly L. Harms, and Paul W. Harms. Merkel cell carcinoma: updates in tumor biology, emerging therapies, and preclinical models. Frontiers in Oncology, Jul 2024. URL: https://doi.org/10.3389/fonc.2024.1413793, doi:10.3389/fonc.2024.1413793. This article has 21 citations.
(pedersen2024merkelcellcarcinoma pages 14-15): Elisabeth A. Pedersen, Monique E. Verhaegen, Mallory K. Joseph, Kelly L. Harms, and Paul W. Harms. Merkel cell carcinoma: updates in tumor biology, emerging therapies, and preclinical models. Frontiers in Oncology, Jul 2024. URL: https://doi.org/10.3389/fonc.2024.1413793, doi:10.3389/fonc.2024.1413793. This article has 21 citations.
(prakash2023evolvingapplicationsof pages 2-4): Varsha Prakash, Ling Gao, and Soo-Jeong Park. Evolving applications of circulating tumor dna in merkel cell carcinoma. Cancers, 15:609, Jan 2023. URL: https://doi.org/10.3390/cancers15030609, doi:10.3390/cancers15030609. This article has 13 citations.
(prakash2023evolvingapplicationsof pages 4-5): Varsha Prakash, Ling Gao, and Soo-Jeong Park. Evolving applications of circulating tumor dna in merkel cell carcinoma. Cancers, 15:609, Jan 2023. URL: https://doi.org/10.3390/cancers15030609, doi:10.3390/cancers15030609. This article has 13 citations.
(d’angelo2024firstlineavelumabtreatment pages 4-6): S.P. D’Angelo, C. Lebbé, L. Mortier, A.S. Brohl, N. Fazio, J.-J. Grob, N. Prinzi, G.J. Hanna, J.C. Hassel, F. Kiecker, A. von Heydebreck, G. Güzel, and P. Nghiem. First-line avelumab treatment in patients with metastatic merkel cell carcinoma: 4-year follow-up from part b of the javelin merkel 200 study. ESMO Open, 9:103461, May 2024. URL: https://doi.org/10.1016/j.esmoop.2024.103461, doi:10.1016/j.esmoop.2024.103461. This article has 29 citations and is from a domain leading peer-reviewed journal.
(averbuch2023avelumabforthe pages 4-5): Itamar Averbuch, Ronen Stoff, Mor Miodovnik, Shlomit Fennig, Gil Bar‐Sela, Alexander Yakobson, Jonathan Daliot, Nethanel Asher, and Eyal Fenig. Avelumab for the treatment of locally advanced or metastatic merkel cell carcinoma—a multicenter real‐world experience in israel. Cancer Medicine, 12:12065-12070, Apr 2023. URL: https://doi.org/10.1002/cam4.5890, doi:10.1002/cam4.5890. This article has 16 citations and is from a peer-reviewed journal.
(d’angelo2024firstlineavelumabtreatment media 30169c3d): S.P. D’Angelo, C. Lebbé, L. Mortier, A.S. Brohl, N. Fazio, J.-J. Grob, N. Prinzi, G.J. Hanna, J.C. Hassel, F. Kiecker, A. von Heydebreck, G. Güzel, and P. Nghiem. First-line avelumab treatment in patients with metastatic merkel cell carcinoma: 4-year follow-up from part b of the javelin merkel 200 study. ESMO Open, 9:103461, May 2024. URL: https://doi.org/10.1016/j.esmoop.2024.103461, doi:10.1016/j.esmoop.2024.103461. This article has 29 citations and is from a domain leading peer-reviewed journal.
(d’angelo2024firstlineavelumabtreatment media a5f140c8): S.P. D’Angelo, C. Lebbé, L. Mortier, A.S. Brohl, N. Fazio, J.-J. Grob, N. Prinzi, G.J. Hanna, J.C. Hassel, F. Kiecker, A. von Heydebreck, G. Güzel, and P. Nghiem. First-line avelumab treatment in patients with metastatic merkel cell carcinoma: 4-year follow-up from part b of the javelin merkel 200 study. ESMO Open, 9:103461, May 2024. URL: https://doi.org/10.1016/j.esmoop.2024.103461, doi:10.1016/j.esmoop.2024.103461. This article has 29 citations and is from a domain leading peer-reviewed journal.